A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

NCT07286032 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients With Chemotherapy-Induced Thrombocytopenia

Interventions

DRUG: Hetrombopag Olamine
DRUG: Hetrombopag Olamine ；Hetrombopag Olamine Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.